DLL4 and cancer: Notwithstanding these limitations, we nevertheless posit that our data provides important clues as to the molecular events involved in CRC drug-induced SD which are important not only in the ambit of standard of care chemotherapy-induced toxicities, but may also be relevant in the emerging field of anti-DLL4 cancer immunotherapies.